Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Type 2 Myocardial Infarctions
NCT04838808Phase 3Completed
- Sponsor
- University of Alberta
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in type 2 myocardial infarction (T2MI), sponsored by University of Alberta. Started Apr 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
type 2 myocardial infarction (T2MI)
Beyond the preview
Go deeper on NCT04838808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838808.